SEP 24, 2019 5:16 AM PDT

Electronic "nose" sniffs out the best cancer treatment

Can you imagine an electronic device that is capable of figuring out which lung cancer patients will respond best to immunotherapy? If so, now try to imagine that device in the quaint form of a nose. Hah! Well, give a warm welcome to eNose, the electronic nose that detects chemicals in the breath of lung cancer patients and is able to identify with 85% accuracy which patients will or will not respond to immunotherapy.

The news about eNose was published in a study recently in the journal Annals of Oncology and comes from researchers led by Professor Michel van den Heuvel, who is a professor of thoracic oncology at the Radboud University Medical Centre in The Netherlands.

While we have known for some time that dogs' noses are capable of detecting disease, the new eNose is an entirely new concept to precision medicine. Photo: Pixabay

Professor van den Heuvel commented, "The introduction of immunotherapy has dramatically improved the treatment of advanced-stage non-small cell lung cancer but unfortunately it is only effective in a subset of patients, which was about 20% when we started the study. Currently, there is no test available that can accurately predict who will benefit from this treatment, apart from PD-L1 testing by immunohistochemistry. This is today's biomarker of choice, despite its analytic and predictive limitations, when making clinical decisions about whether or not to treat a patient with immunotherapy."

The PD-L1 testing that the professor refers to immunohistochemistry (IHC) tests that sample tissues for the presence of the protein called programmed death-ligand 1 (PD-L1), which is the target for anti-PD 1 therapies. Needless to say, tissue sampling is a lengthy and invasive procedure.

Ms. Rianne de Vries, co-first author of the study, stated: "We hypothesized that exhaled breath analysis using eNose technology might be a non-invasive and rapid alternative to the current standard and would enable doctors to avoid treating patients with immunotherapy to which they would not respond."

So, what exactly does eNose look like and how does it work? Imagine you have been diagnosed with non-small cell lung cancer and are trying to figure out if immunotherapy is an appropriate treatment for you. With eNose, you could take a deep breath, hold it for 5 seconds, and exhale into the nose. The device will then be able to read the chemicals in your breath called volatile organic compounds (VOCs), which change depending on the metabolic processes going on in your body.

As Ms. de Vries explains further, “The eNose sensors respond to the complete mixture of VOCs in the exhaled breath; each sensor has its highest sensitivity to a different group of molecules. The sensor readings are sent directly to and stored at an online server for real-time processing of the data and for ambient air correction because the air that you exhale is influenced by the air that you inhale. The measurement takes less than a minute, and the results are compared to an online database where machine-learning algorithms immediately identify whether or not the patient is likely to respond to anti-PD1 therapy."

In conducting their study, the researchers found that the eNose had an 85% accuracy rate in detecting which patients will respond to immunotherapy. Because the device is relatively inexpensive (it is currently in the production process), the authors hope that it will offer an alternative to IHC, with better results for patients.

"Our findings show that breath analysis by eNose can potentially avoid application of ineffective treatment to patients that are identified by eNose as being non-responders to immunotherapy, which in our study was 24% of the patients. This means that in 24% of NSCLC patients this treatment could be avoided, without denying anyone effective treatment,” said co-first author Dr. Mirte Muller.

Sources: Science Daily, Annals of Oncology

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
AUG 18, 2021
Cannabis Sciences
Cancer Patients Use Less Cannabis than General Public
AUG 18, 2021
Cancer Patients Use Less Cannabis than General Public
Despite increasing legalization for recreational cannabis across the US, cancer patients have largely abstained from usi ...
SEP 20, 2021
Cancer
An Established Ovarian Cancer Antigen Presents a Promising Therapeutic Target
SEP 20, 2021
An Established Ovarian Cancer Antigen Presents a Promising Therapeutic Target
For the past several decades, cancer antigen 125 (CA 125), a protein located on the surface of ovarian cancer cells, has ...
SEP 23, 2021
Drug Discovery & Development
The FDA approves the first and only oral treatment for a certain non-small cell lung cancer.
SEP 23, 2021
The FDA approves the first and only oral treatment for a certain non-small cell lung cancer.
Last week, the United States Food and Drug Administration (FDA) granted approval for the first oral therapy to ...
OCT 18, 2021
Cancer
The History of Immunotherapy: Toxins, Targets & T Cells
OCT 18, 2021
The History of Immunotherapy: Toxins, Targets & T Cells
Cancer immunotherapy, a treatment that directly enhances a patient’s immune system, is typically perceived as a mo ...
NOV 01, 2021
Cancer
Gut Microbiota Promotes Resistance to Prostate Cancer Therapy
NOV 01, 2021
Gut Microbiota Promotes Resistance to Prostate Cancer Therapy
  The American Cancer Society estimates that nearly 250,000 men in the United States will be diagnosed with prostat ...
NOV 24, 2021
Cannabis Sciences
Can Cannabis Treat Chemotherapy-induced Peripheral Neuropathy?
NOV 24, 2021
Can Cannabis Treat Chemotherapy-induced Peripheral Neuropathy?
Platinum-based chemotherapies such as oxaliplatin are used to treat gastrointestinal tumors, especially in the advanced ...
Loading Comments...